Synthetic biology startup Allozymes has made three strategic hires to strengthen the firm’s senior management, while Endowus has made two strategic hires — head of investments and director of research.
Deep tech startup Allozymes adds 3 strategic hires
Singapore-based synthetic biology startup Allozymes has made three strategic hires to strengthen the firm’s senior management.
The new hires are Ali Fallah-Araghi, who joins as director of protein engineering; Tiago Resende, senior computation biologist; and Deepak Raghothaman, director of business development at Allozymes.
Ali Fallah-Araghi is director of protein of engineering, where he leverages ultrahigh throughput screening platform for increasing the activity, specificity, and stability of enzymes. Prior to Allozymes, Fallah-Araghi spent 10 years at Novozymes, where he rotated through various roles including science manager, department manager, and scouting for innovative technologies.
Tiago Resende is a senior computational biologist, where he leverages high-throughput platform with the integration of cloud-based systems, data science and bioinformatics. Prior to this, he spent many years at Amyris Inc as a computational biologist. Resende obtained his PhD in bioengineering systems from the MIT-Portugal programme. He is currently based in Portugal.
Deepak Raghothaman is director of business development, where he leads the use of technology for global innovation platforms and bring product pipelines from seed to scale. Prior to Alloyzmes, Raghothaman was at Ferrero for 5 years where he led open innovation and strategic commercial partnerships for APAC and managing Asia raw materials in agri-foodtech, biotech, sustainability and applied digital solutions.
The appointments come at a time when Allozymes is about to begin its Series A fundraising process as reported by DealStreetAsia last month. The Xora Innovation-backed firm was last reported to be looking at a $30 million fundraise, which would provide the capital ammunition required to accelerate the growth and rollout of its enzyme library and biotechnology platform.
Endowus makes key strategic hires
Endowus, Singapore’s digital wealth platform, has made two strategic hires, with the appointment of Sean Wong as its Head of Investments, and Min Axthelm as its Director of Research.
In this role, Wong will oversee the management of Endowus’ investment and advisory solutions, as well as lead the investment office in optimising portfolio strategies and fund selections to drive growth.
Wong will also be focusing on engaging with fund management companies to cultivate strategic relationships to broaden the range of investment solutions and market innovations in the sector.
Wong began his career with BBR Partners, LLC, a boutique multi-family office in New York, focused on developing integrated investment solutions for ultra-high net-worth individuals and families.
Prior to Endowus, he was an Executive Director in the Investment Management Services (IMS) team at Morgan Stanley Private Wealth Management Asia, serving as their Head of Offerings.
Axthelm joins from Morgan Stanley in New York, where she was Lead Analyst with its Wealth Management Global Investment Office, overseeing the due diligence process from inception to completion for US Equity strategies and mutual funds.
“I am very excited to welcome Sean and Min to the growing Endowus Investment Office in key leadership positions. Their extensive knowledge and expertise in the funds industry for both private wealth and asset management is critical to helping our investors to achieve good outcomes. Their strong market and product knowledge and extensive experience in fund selection and fund manager due diligence as well as portfolio construction, will help our clients make better choices and achieve better outcomes, as we strive to do better for them and help lead the industry in best practices,” said Samuel Rhee, Chairman and Chief Investment Officer of Endowus.